6XG3
The crystal structure of Papain-Like Protease of SARS CoV-2 , C111S mutant, at room temperature
Summary for 6XG3
| Entry DOI | 10.2210/pdb6xg3/pdb |
| Related | 6W9C 6WRH 6WZU |
| Descriptor | Non-structural protein 3, ZINC ION, PHOSPHATE ION, ... (5 entities in total) |
| Functional Keywords | covid-19, coronavirus, sars, cov-2, papain-like protease, idp51000, center for structural genomics of infectious diseases, csgid, hydrolase |
| Biological source | Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) |
| Total number of polymer chains | 1 |
| Total formula weight | 36123.53 |
| Authors | Osipiuk, J.,Tesar, C.,Jedrzejczak, R.,Endres, M.,Joachimiak, A.,Center for Structural Genomics of Infectious Diseases (CSGID) (deposition date: 2020-06-16, release date: 2020-06-24, Last modification date: 2023-10-18) |
| Primary citation | Osipiuk, J.,Azizi, S.A.,Dvorkin, S.,Endres, M.,Jedrzejczak, R.,Jones, K.A.,Kang, S.,Kathayat, R.S.,Kim, Y.,Lisnyak, V.G.,Maki, S.L.,Nicolaescu, V.,Taylor, C.A.,Tesar, C.,Zhang, Y.A.,Zhou, Z.,Randall, G.,Michalska, K.,Snyder, S.A.,Dickinson, B.C.,Joachimiak, A. Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors. Nat Commun, 12:743-743, 2021 Cited by PubMed Abstract: The pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continues to expand. Papain-like protease (PLpro) is one of two SARS-CoV-2 proteases potentially targetable with antivirals. PLpro is an attractive target because it plays an essential role in cleavage and maturation of viral polyproteins, assembly of the replicase-transcriptase complex, and disruption of host responses. We report a substantive body of structural, biochemical, and virus replication studies that identify several inhibitors of the SARS-CoV-2 enzyme. We determined the high resolution structure of wild-type PLpro, the active site C111S mutant, and their complexes with inhibitors. This collection of structures details inhibitors recognition and interactions providing fundamental molecular and mechanistic insight into PLpro. All compounds inhibit the peptidase activity of PLpro in vitro, some block SARS-CoV-2 replication in cell culture assays. These findings will accelerate structure-based drug design efforts targeting PLpro to identify high-affinity inhibitors of clinical value. PubMed: 33531496DOI: 10.1038/s41467-021-21060-3 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.48 Å) |
Structure validation
Download full validation report
